Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven IgA nephropathy~* GFR \> 30 mL/min~* Urinary protein \> 700 mg/day~* Stable serum creatinine~* Urine CCL2/creatinine \> 250 pg/mg~* Stable doses of medications~* ACEI and/or ARB maximized to control hypertension and proteinuria~Exclusion Criteria:~* Other causes of nephropathy~* Pregnant or nursing females~* Prednisone \> 10 mg/day~* Other prohibited medications~* BP \> 140/90~* BMI \> 35~* Concurrent infection requiring treatment~* Clinical significant concurrent medical conditions~* Known allergy or sensitivity to formulation ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).